This also applies for patients co-infected with HIV, where pre-treatment IP-10 levels below 150 pg/mL are predictive of a favorable response, and may thus be useful in encouraging these otherwise difficult-to-treat patients to initiate therapy. The pathogen Leishmania major utilizes a protease, GP63, that cleaves CXCL10, implicating CXCL10 in host defense mechanisms of certain intracellular pathogens like Leishmania.
Furthermore, this also pertains to HIV-infected patients who have co-infection, where pre-treatment IP-10 levels below 150 pg/mL are predictive of a positive outcome, and may be beneficial in persuading these hard-to-treat patients to start treatment. The parasite Leishmania major utilizes an enzyme, GP63, that breaks down CXCL10, implying CXCL10's role in the defense mechanisms of certain internal pathogens such as Leishmania.